[go: up one dir, main page]

MY191875A - Solid dosage form - Google Patents

Solid dosage form

Info

Publication number
MY191875A
MY191875A MYPI2015000938A MYPI2015000938A MY191875A MY 191875 A MY191875 A MY 191875A MY PI2015000938 A MYPI2015000938 A MY PI2015000938A MY PI2015000938 A MYPI2015000938 A MY PI2015000938A MY 191875 A MY191875 A MY 191875A
Authority
MY
Malaysia
Prior art keywords
dosage form
solid dosage
active material
biologically active
oral cavity
Prior art date
Application number
MYPI2015000938A
Inventor
Chin Beng Stephen Lim
Vivian Bruce Sunderland
Yip Hang Eddy Lee
Original Assignee
Ix Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012238330A external-priority patent/AU2012238330B1/en
Application filed by Ix Biopharma Ltd filed Critical Ix Biopharma Ltd
Publication of MY191875A publication Critical patent/MY191875A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

There is provided a solid dosage form adapted for the release of a biologically active material in the oral cavity wherein the dosage form comprises at least one biologically active material, and at least one matrix forming agent, wherein the dosage form substantially dissolves in the oral cavity. A method of producing the same and a kit comprising the same are also provided.
MYPI2015000938A 2012-10-11 2013-10-11 Solid dosage form MY191875A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2012238330A AU2012238330B1 (en) 2010-10-26 2012-10-11 Fast Dissolving Solid Dosage Form
AU2013200682A AU2013200682C1 (en) 2010-10-26 2013-02-08 Fast Dissolving Solid Dosage Form
AU2013200684A AU2013200684B1 (en) 2010-10-26 2013-02-08 Fast Dissolving Solid Dosage Form
PCT/IB2013/002594 WO2014057351A1 (en) 2012-10-11 2013-10-11 Solid dosage form

Publications (1)

Publication Number Publication Date
MY191875A true MY191875A (en) 2022-07-18

Family

ID=50478109

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015000938A MY191875A (en) 2012-10-11 2013-10-11 Solid dosage form

Country Status (11)

Country Link
EP (1) EP2906201A4 (en)
JP (1) JP2015533155A (en)
KR (1) KR20150063567A (en)
CN (2) CN104812378B (en)
CA (1) CA2886573C (en)
HK (1) HK1208353A1 (en)
IL (2) IL238104B (en)
MY (1) MY191875A (en)
NZ (1) NZ706302A (en)
SG (1) SG11201502425WA (en)
WO (1) WO2014057351A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6217052B2 (en) * 2016-04-21 2017-10-25 邦赫 小牧 Effervescent tablet for oral cleaning
JP2019519487A (en) 2016-05-05 2019-07-11 アクエスティブ セラピューティクス インコーポレイテッド Delivery enhancing epinephrine composition
JP2017193547A (en) * 2017-05-08 2017-10-26 邦赫 小牧 Foaming tablet for oral cleaning
CN111132670A (en) * 2017-09-27 2020-05-08 阿奎斯蒂弗医疗股份有限公司 Pharmaceutical composition with enhanced penetration
IL273485B2 (en) * 2017-09-27 2024-11-01 Aquestive Therapeutics Inc Preparations for improved administration of epinephrine and drug meters
IT201800003507A1 (en) * 2018-03-13 2019-09-13 Fulton Medicinali S P A SUBLINGUAL TABLET INCLUDING SILDENAFIL CITRATE
NZ777261A (en) * 2019-01-07 2024-11-29 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression
CN109846841B (en) * 2019-01-18 2021-06-01 西安力邦医药科技有限责任公司 Quick-acting clobazam oral freeze-dried preparation and preparation method thereof
US20220062200A1 (en) * 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11382873B1 (en) * 2021-01-08 2022-07-12 Vitalis Analgesics LLC Oral administration of ketamine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
AU2001273545A1 (en) * 2000-07-19 2002-01-30 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
EP1599186B1 (en) * 2003-02-24 2013-04-10 Pharmaceutical Productions Inc. Transmucosal drug delivery system
CA2612917A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
WO2009045022A2 (en) * 2007-10-03 2009-04-09 C.L. Pharm Edible film
KR100905027B1 (en) * 2007-10-03 2009-06-30 (주)씨엘팜 Edible Film
DE102008014533A1 (en) * 2008-03-15 2009-09-17 Lts Lohmann Therapie-Systeme Ag Gingival wafer
US8623401B2 (en) * 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
CN102933207B (en) * 2009-10-30 2018-02-02 Ix生物医药有限公司 Fast-dissolving solid formulation
BR112012024092A2 (en) * 2010-03-23 2016-09-06 Bioalliance Pharma fast oral dissolving film
FR2967066B1 (en) * 2010-11-04 2013-06-14 Ethypharm Sa SUBLINGUAL USE OF NON-COMPRESSED MICROGRANULES
JP5841433B2 (en) * 2012-01-11 2016-01-13 日東電工株式会社 Intraoral film-form base and preparation
ES2766326T3 (en) * 2013-03-15 2020-06-12 Aerpio Therapeutics Inc Compositions, formulations and methods to treat eye diseases

Also Published As

Publication number Publication date
EP2906201A4 (en) 2016-10-19
NZ706302A (en) 2017-07-28
JP2015533155A (en) 2015-11-19
CA2886573C (en) 2019-04-02
CN104812378A (en) 2015-07-29
HK1208353A1 (en) 2016-03-04
IL273076A (en) 2020-04-30
WO2014057351A1 (en) 2014-04-17
SG11201502425WA (en) 2015-05-28
EP2906201A1 (en) 2015-08-19
CN104812378B (en) 2017-12-01
IL238104B (en) 2020-03-31
KR20150063567A (en) 2015-06-09
CN107669649A (en) 2018-02-09
CA2886573A1 (en) 2014-04-17
IL238104A0 (en) 2015-05-31

Similar Documents

Publication Publication Date Title
MY150626A (en) Fast dissolving solid dosage form
MY191875A (en) Solid dosage form
MX2015017036A (en) Method for producing renal precursor cells, and drug containing renal precursor cells.
MX2013008850A (en) Compositions and methods for treating cardiovascular diseases.
EP2279227A4 (en) Anionic latex as a carrier for active ingredients and methods for making and using the same
PH12013501524A1 (en) Topical minocycline compositions and methods of using the same
CA141113S (en) Dispenser for pharmaceutical powder formulations
JO3052B1 (en) Dividable galenical form allowing modified release of the active ingredient
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MX2014004862A (en) Acrylic polymer formulations.
PE20140255A1 (en) DISPERSIBLE TABLET IN ORAL FORM
DOP2012000170A (en) PROCESS FOR THE MANUFACTURE OF AN ACTIVE PHARMACEUTICALLY AGENT
PH12014502834A1 (en) Pharmaceutical form for extended release of active substances
PH12014501240A1 (en) Film containing compositions
MY162688A (en) Oral care compositions
MX363549B (en) Antidiabetic solid pharmaceutical compositions.
MX2014008390A (en) Romidepsin formulations and uses thereof.
MX349563B (en) Pharmaceutical formulation of nanonised fenofibrate.
MY197131A (en) Fast dissolving solid dosage form
MX2013012551A (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease.
EP2799043A4 (en) Vaginal ring including meloxicam and an agent for modulating the release of the active principle, which can be used as a continuous-use contraceptive in women
AU340341S (en) A mold for pastries
AU340339S (en) A mold for pastries
AU340340S (en) A mold for pastries
UA65038U (en) method for treatment of patients with tocomanias